Search

Pharmagest Interactive

Fechado

0

Visão Geral

Variação de preço das ações

24h

Atual

Mín

Máximo

Indicadores-chave

By Trading Economics

Rendimento

17M

Vendas

116M

P/E

Médio do Setor

14.267

Rendimento de Dividendos

3.65

Margem de lucro

14.879

Funcionários

1,400

EBITDA

116M

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.65%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

585M

Abertura anterior

0

Fecho anterior

0

Pharmagest Interactive Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

31 de mar. de 2026, 23:31 UTC

Ações em Alta

Stocks to Watch: Nike, RH, NCino

31 de mar. de 2026, 22:35 UTC

Ganhos

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 de abr. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 de mar. de 2026, 23:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 de mar. de 2026, 23:43 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 de mar. de 2026, 23:33 UTC

Conversa de Mercado
Notícias Principais

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 de mar. de 2026, 23:21 UTC

Ganhos

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 de mar. de 2026, 23:14 UTC

Conversa de Mercado
Ganhos

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 de mar. de 2026, 23:12 UTC

Conversa de Mercado

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke 2025 Loss Widens >000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 de mar. de 2026, 21:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 de mar. de 2026, 21:36 UTC

Conversa de Mercado

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 de mar. de 2026, 21:35 UTC

Ganhos

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 de mar. de 2026, 21:35 UTC

Ganhos

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 de mar. de 2026, 21:35 UTC

Ganhos

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 de mar. de 2026, 21:33 UTC

Ganhos

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 de mar. de 2026, 21:32 UTC

Ganhos

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 de mar. de 2026, 21:28 UTC

Ganhos

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 de mar. de 2026, 21:26 UTC

Ganhos

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 de mar. de 2026, 21:25 UTC

Ganhos

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 de mar. de 2026, 21:24 UTC

Conversa de Mercado
Ganhos

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 de mar. de 2026, 21:22 UTC

Ganhos

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 de mar. de 2026, 21:22 UTC

Ganhos

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 de mar. de 2026, 21:21 UTC

Ganhos

Nike's Digital Channel Still Too Promotional, CFO Says

31 de mar. de 2026, 21:20 UTC

Ganhos

Nike CEO: Converse Remains Important to Portfolio

Pharmagest Interactive Previsão

Consenso de Avaliação

By TipRanks

0 ratings

0

Comprar

0

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Pharmagest Interactive

Equasens Société anonyme provides healthcare IT solutions in Europe. The company develops electronic equipment, digital and robotic health, and equipment lease financing solutions. It also offers id., a pharmacy management software suite; id. PATIENT for the exchange of healthcare data; id. VENTE, which facilitates and secures prescription sales; id. COMMANDE, which manages orders and inventory; dispensing robots; Ségur id. services; FARMACLICK, a communication protocol; DIFARM, a modular solution for wholesalers-distributors; and PHARE, a retail management tool. In addition, the company offers patient medication adherence, patient loyalty, point-of-sale commercial performance, piloting pharmacy operations, pharmacy team training, securing pharmacy operations and health data, and digital communication solutions; and in-home nursing services and hospital-at-home, hospitals, and telemedicine solutions. Further, it provides id. DESK, an informative and interactive dashboard; id. UP!, a smartphone app; id. EASYQ, a queuing management solution; Miaterapia, a patient app; and MediStory for tracking patient records; ExpressVitale module; and MEDILINK, a health data hosting provider. Additionally, the company offers KAP&LINK2, a terminal with smart card and NFC reader; eS-KAP-Ad, a mobile device with a pre-loaded software; KAP-INSIDE, a mobile terminal; TI-KAP, which allows access to contact and contactless cards; AUTHENTIFICATEUR, a patented patient authentication system; KAP'TEUR by KAPELSE, a patented universal sensor; and NOVIAcare, which analyzes the behavior and activity of the elderly. It serves nursing homes, hospitals, in-house nursing care and hospital-at-home programs, regional health professional communities, multidisciplinary group practices, and individual healthcare professionals. The company was incorporated in 1996 and is headquartered in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
help-icon Live chat